CLGN (CollPlant Biotechnologies) ROE % Adjusted to Book Value : -27.36% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies ROE % Adjusted to Book Value?

CollPlant Biotechnologies's ROE % for the quarter that ended in Sep. 2024 was -91.93%. CollPlant Biotechnologies's PB Ratio for the quarter that ended in Sep. 2024 was 3.36. CollPlant Biotechnologies's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -27.36%.

CollPlant Biotechnologies ROE % Adjusted to Book Value Historical Data

The historical data trend for CollPlant Biotechnologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies ROE % Adjusted to Book Value Chart

CollPlant Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.25

-15.13

-8.98

CollPlant Biotechnologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-25.97	-23.94	-25.33	-27.11	-27.36

Competitive Comparison of CollPlant Biotechnologies's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CollPlant Biotechnologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's ROE % Adjusted to Book Value falls into.

CollPlant Biotechnologies ROE % Adjusted to Book Value Calculation

CollPlant Biotechnologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-23.16%	/	2.58
	=	-8.98%

CollPlant Biotechnologies's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-91.93%	/	3.36
	=	-27.36%

CollPlant Biotechnologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CPT:Germany

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.